Submitted for Publication: August 22, 2012; final revision received December 11, 2012; accepted January 21, 2013.
Published Online: August 14, 2013. doi:10.1001/jamapsychiatry.2013.1965.
Study concept and design: Sullivan, Miller, Gerstein, Akpunonu, Williamson, Launer.
Acquisition of data: Sullivan, Miller, Horowitz, Marcovina, Johnson, Williamson.
Analysis and interpretation of data: Sullivan, Katon, Lovato, Miller, Murray, Bryan, Marcovina, Yale.
Drafting of the manuscript: Sullivan, Lovato, Miller, Johnson.
Critical revision of the manuscript for important intellectual content: Katon, Miller, Murray, Horowitz, Bryan, Gerstein, Marcovina, Akpunonu, Yale, Williamson, Launer.
Statistical analysis: Lovato, Miller, Marcovina.
Obtained funding: Miller, Murray, Gerstein, Williamson, Launer.
Administrative, technical, and material support: Bryan, Marcovina, Johnson.
Study supervision: Sullivan, Katon, Miller, Launer.
Conflict of Interest Disclosures: The following companies provided study drugs, equipment, or supplies: Abbott Laboratories, Amylin Pharmaceuticals, AstraZeneca, Bayer HealthCare, Closer Healthcare, GlaxoSmithKline, King Pharmaceuticals, Merck, Novartis, Novo Nordisk, Omron Healthcare, sanofi-aventis, and Schering-Plough.
Funding/Support: ACCORD-MIND was funded through an intra-agency agreement between the National Institute on Aging and National Heart, Lung, and Blood Institute (grant AG-0002) and the National Institute on Aging Intramural Research Program. ACCORD was funded by National Heart, Lung, and Blood Institute grants N01-HC-95178; N01-HC-95179; N01-HC-95180; N01-HC-95181; N01-HC-95182; N01-HC-95183; and N01-HC-95184.